olmesartan axetil + amlodipine + hydrochlorothiazide

olmesartan axetil + amlodipine + hydrochlorothiazide is a fixed-dose triple combination therapy indicated for the treatment of primary hypertension. This combination targets three distinct physiological pathways to achieve blood pressure control, combining an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. Olmesartan acts as a selective AT1 receptor antagonist, preventing the vasoconstrictive effects of angiotensin II. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle, resulting in peripheral vasodilation. Hydrochlorothiazide acts on the renal distal tubules to increase the excretion of sodium and water, thereby reducing extracellular fluid volume. Clinical development and trials for this combination in China have been notably led by institutions such as Ruijin Hospital, affiliated with the Shanghai Jiaotong University School of Medicine. This triple therapy is typically reserved for patients whose blood pressure is not adequately controlled on dual therapy.

Brand names

TribenzorSevikar HCT

Other names

olmesartan medoxomil + amlodipine + hydrochlorothiazideolmesartan medoxomil/amlodipine/hydrochlorothiazideolmesartan/amlodipine/HCTZ